[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200904500A2 - Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. - Google Patents

Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.

Info

Publication number
TR200904500A2
TR200904500A2 TR2009/04500A TR200904500A TR200904500A2 TR 200904500 A2 TR200904500 A2 TR 200904500A2 TR 2009/04500 A TR2009/04500 A TR 2009/04500A TR 200904500 A TR200904500 A TR 200904500A TR 200904500 A2 TR200904500 A2 TR 200904500A2
Authority
TR
Turkey
Prior art keywords
ezetimibe
nanocrystals
preparation
methods
pharmaceutical formulations
Prior art date
Application number
TR2009/04500A
Other languages
English (en)
Inventor
Öner Levent
Gülsün Tuğba
Nesli̇han Gürsoy Reyhan
Original Assignee
Öner Levent
Nesli̇han Gürsoy Reyhan
Gülsün Tuğba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Öner Levent, Nesli̇han Gürsoy Reyhan, Gülsün Tuğba filed Critical Öner Levent
Priority to TR2009/04500A priority Critical patent/TR200904500A2/tr
Publication of TR200904500A2 publication Critical patent/TR200904500A2/tr
Priority to PCT/TR2010/000106 priority patent/WO2010144066A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş, ezetimib veya famıasötik olarak uygun bır tuzunun nanokristallerinin hazırlanması için bir yöntem ve bu yöntemle hazırlanan nanokristalleri içeren ezetimib farmasötik formülasyonları ve hazırlanması ile ilgilidir.
TR2009/04500A 2009-06-10 2009-06-10 Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. TR200904500A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2009/04500A TR200904500A2 (tr) 2009-06-10 2009-06-10 Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
PCT/TR2010/000106 WO2010144066A1 (en) 2009-06-10 2010-06-04 Method for the preparation of ezetimib nanocrystals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2009/04500A TR200904500A2 (tr) 2009-06-10 2009-06-10 Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.

Publications (1)

Publication Number Publication Date
TR200904500A2 true TR200904500A2 (tr) 2009-10-21

Family

ID=42740287

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2009/04500A TR200904500A2 (tr) 2009-06-10 2009-06-10 Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.

Country Status (2)

Country Link
TR (1) TR200904500A2 (tr)
WO (1) WO2010144066A1 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
EP2700632A4 (en) * 2011-04-18 2014-09-03 Hefei Beini Medical Technology Company Ltd METHOD FOR CLEANING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND PRODUCING NANOPARTICLES THEREFOR
CN103655481A (zh) * 2012-09-18 2014-03-26 江苏柯菲平医药有限公司 一种依折麦布口服制剂制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20020115696A1 (en) 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
CA2563051A1 (en) 2001-01-26 2002-08-01 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2003230692A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
EA200501001A1 (ru) 2002-12-31 2005-12-29 Нектар Терапьютикс Фармацевтический состав с нерастворимым активным агентом
MXPA06015220A (es) 2004-06-21 2007-12-13 Nektar Therapeutics Composiciones comprendiendo anfotericina b, metodos y sistemas.
US20060160785A1 (en) * 2004-12-03 2006-07-20 Judith Aronhime Ezetimibe polymorphs
ATE454134T1 (de) * 2005-04-13 2010-01-15 Abbott Gmbh & Co Kg Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
US20060234996A1 (en) 2005-04-14 2006-10-19 Itai Adin Novel crystalline form of ezetimibe and processes for the preparation thereof
WO2007092088A1 (en) 2005-12-28 2007-08-16 Nektar Therapeutics Compositions comprising amphotericin b
KR20080096851A (ko) 2006-03-06 2008-11-03 테바 파마슈티컬 인더스트리즈 리미티드 에제티미베 조성물
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008089984A2 (en) 2007-01-24 2008-07-31 Krka Process for the preparation of ezetimibe and derivatives thereof
EP2125938A2 (en) * 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
EP2120882A2 (en) 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法

Also Published As

Publication number Publication date
WO2010144066A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201390203A1 (ru) Способы получения тубулизинов
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
MX340090B (es) Analogos de spliceostatina.
EA201270722A1 (ru) Формы рифаксимина и их применение
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
EA201171151A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
TR201902439T4 (tr) Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri .
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MY187718A (en) Pharmaceutical formulations
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
BR112014002845A2 (pt) “composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto”
PH12015500823A1 (en) Modified release formulations for oprozomib
UA118562C2 (uk) Модулятори рецептора cxcr7
CR20120146A (es) Derivados de espirolactama y usos de los mismos
TR200904500A2 (tr) Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
EA201400444A1 (ru) Производные 2-оксопиперидинила